Abridge valuation, funding and investors
Abridge works in generative AI solutions development, based in Philadelphia, United States. Founded in 2018, it has about 677 employees.
- Last round
- Series E · $316M · Apr 2026
- Valuation at last round
- $5.30B
- Headcount
- 677 · growing
- Grade
- A
- Founded
- 2018
Abridge valuation today
VCMC values Abridge at $6.2B today, with a range of $4.6B to $8.2B and a grade of A. The valuation starts from its last funding round, a Series E round in Apr 2026.
Valuation by date (112 rows)
Each point is what the model would have shown on that date, using only what was known then; before its first round, a company is valued as a startup because it later raised.
| Date | Valuation | Range | Predicted in 1 yr | Phase | Headcount | Trend | Grade | Winding-down probability |
|---|---|---|---|---|---|---|---|---|
| 1 Jan 2018 | $8.90M | $3.24M – $24.4M | $12.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 Feb 2018 | $9.14M | $3.33M – $25.1M | $12.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Mar 2018 | $9.36M | $3.41M – $25.7M | $12.8M (+37%) | before first round | – | unknown | D | 0% |
| 1 Apr 2018 | $9.62M | $3.50M – $26.4M | $13.2M (+37%) | before first round | – | unknown | D | 0% |
| 1 May 2018 | $9.87M | $3.59M – $27.1M | $13.5M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jun 2018 | $10.1M | $3.69M – $27.8M | $13.9M (+37%) | before first round | – | unknown | D | 0% |
| 1 Jul 2018 | $10.4M | $3.79M – $28.6M | $14.3M (+37%) | before first round | – | unknown | D | 0% |
| 1 Aug 2018 | $10.7M | $3.89M – $29.4M | $14.4M (+35%) | before first round | – | unknown | D | 0% |
| 1 Sep 2018 | $11.0M | $4.00M – $30.2M | $14.5M (+32%) | before first round | – | unknown | D | 0% |
| 1 Oct 2018 | $11.3M | $4.10M – $30.9M | $14.7M (+30%) | before first round | – | unknown | D | 0% |
| 1 Nov 2018 | $11.6M | $4.21M – $31.8M | $14.8M (+28%) | before first round | – | unknown | D | 0% |
| 1 Dec 2018 | $11.9M | $4.32M – $32.6M | $14.9M (+26%) | before first round | – | unknown | D | 0% |
| 1 Jan 2019 | $12.2M | $4.44M – $33.5M | $15.1M (+24%) | before first round | – | unknown | D | 0% |
| 1 Feb 2019 | $33.4M | $21.9M – $101M | $66.7M (+100%) | after a round | – | unknown | C | 0% |
| 1 Mar 2019 | $35.2M | $21.9M – $101M | $66.7M (+89%) | after a round | – | unknown | C | 0% |
| 1 Apr 2019 | $37.4M | $21.9M – $101M | $66.7M (+78%) | after a round | – | unknown | C | 0% |
| 1 May 2019 | $39.5M | $21.9M – $101M | $66.7M (+69%) | after a round | – | unknown | C | 0% |
| 1 Jun 2019 | $41.9M | $21.9M – $101M | $66.7M (+59%) | after a round | – | unknown | C | 0% |
| 1 Jul 2019 | $44.4M | $21.9M – $101M | $66.7M (+50%) | after a round | – | unknown | C | 0% |
| 1 Aug 2019 | $47.1M | $21.9M – $101M | $66.7M (+42%) | after a round | – | unknown | C | 0% |
| 1 Sep 2019 | $49.9M | $21.9M – $101M | $66.7M (+33%) | after a round | – | unknown | C | 0% |
| 1 Oct 2019 | $52.9M | $21.9M – $101M | $66.7M (+26%) | after a round | – | unknown | C | 0% |
| 1 Nov 2019 | $56.1M | $21.9M – $101M | $66.7M (+19%) | after a round | – | unknown | C | 0% |
| 1 Dec 2019 | $59.4M | $21.9M – $101M | $66.7M (+12%) | after a round | – | unknown | C | 0% |
| 1 Jan 2020 | $62.9M | $21.9M – $101M | $66.7M (+6%) | after a round | – | unknown | C | 0% |
| 1 Feb 2020 | $66.7M | $21.9M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Mar 2020 | $66.7M | $20.9M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Apr 2020 | $66.7M | $19.8M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 May 2020 | $66.7M | $18.9M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Jun 2020 | $66.7M | $17.9M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Jul 2020 | $66.7M | $17.1M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Aug 2020 | $66.7M | $16.2M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Sep 2020 | $66.7M | $15.4M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Oct 2020 | $66.7M | $14.7M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Nov 2020 | $66.7M | $13.9M – $101M | $66.7M (0%) | after a round | – | unknown | C | 0% |
| 1 Dec 2020 | $66.7M | $13.3M – $101M | $66.7M (0%) | after a round | – | unknown | D | 0% |
| 1 Jan 2021 | $66.7M | $12.6M – $101M | $66.7M (0%) | after a round | – | unknown | D | 0% |
| 1 Feb 2021 | $66.7M | $12.0M – $101M | $66.7M (0%) | after a round | – | unknown | D | 0% |
| 1 Mar 2021 | $66.7M | $11.5M – $101M | $66.7M (0%) | after a round | – | unknown | D | 0% |
| 1 Apr 2021 | $66.7M | $10.9M – $101M | $66.7M (0%) | after a round | – | unknown | D | 0% |
| 1 May 2021 | $66.7M | $10.4M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Jun 2021 | $66.7M | $9.85M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Jul 2021 | $66.7M | $9.37M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Aug 2021 | $66.7M | $8.91M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Sep 2021 | $66.7M | $8.46M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Oct 2021 | $66.7M | $8.06M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Nov 2021 | $66.7M | $7.66M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Dec 2021 | $66.7M | $7.29M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Jan 2022 | $66.7M | $6.93M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Feb 2022 | $66.7M | $6.58M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Mar 2022 | $66.7M | $6.29M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Apr 2022 | $66.7M | $5.98M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 May 2022 | $66.7M | $5.69M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Jun 2022 | $66.7M | $5.41M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Jul 2022 | $66.7M | $5.15M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 1 Aug 2022 | $66.7M | $4.89M – $101M | $66.7M (0%) | after a round | 21 | unknown | D | 0% |
| 12 Aug 2022 | $69.6M | $45.6M – $190M | $125M (+80%) | after a round | 21 | unknown | C | 0% |
| 1 Sep 2022 | $71.8M | $45.6M – $190M | $125M (+74%) | after a round | 21 | unknown | C | 0% |
| 1 Oct 2022 | $75.4M | $45.6M – $190M | $125M (+66%) | after a round | 21 | unknown | C | 0% |
| 1 Nov 2022 | $79.2M | $45.6M – $190M | $125M (+58%) | after a round | 21 | unknown | C | 0% |
| 1 Dec 2022 | $83.2M | $45.6M – $190M | $125M (+50%) | after a round | 21 | unknown | C | 0% |
| 1 Jan 2023 | $87.4M | $45.6M – $190M | $125M (+43%) | after a round | 21 | unknown | C | 0% |
| 1 Feb 2023 | $91.9M | $45.6M – $190M | $125M (+36%) | after a round | 21 | unknown | C | 0% |
| 1 Mar 2023 | $96.1M | $45.6M – $190M | $125M (+30%) | after a round | 21 | unknown | C | 0% |
| 1 Apr 2023 | $101M | $45.6M – $190M | $125M (+24%) | after a round | 21 | unknown | C | 0% |
| 1 May 2023 | $106M | $45.6M – $190M | $125M (+18%) | after a round | 35 | unknown | C | 0% |
| 1 Jun 2023 | $111M | $45.6M – $190M | $125M (+12%) | after a round | 35 | unknown | C | 0% |
| 1 Jul 2023 | $117M | $45.6M – $190M | $125M (+7%) | after a round | 35 | unknown | C | 0% |
| 1 Aug 2023 | $123M | $45.6M – $190M | $125M (+2%) | after a round | 35 | unknown | C | 0% |
| 1 Sep 2023 | $125M | $44.1M – $190M | $125M (0%) | after a round | 35 | unknown | C | 0% |
| 1 Oct 2023 | $125M | $46.7M – $190M | $125M (0%) | after a round | 51 | growing | C | 0% |
| 27 Oct 2023 | $183M | $129M – $388M | $274M (+50%) | after a round | 51 | growing | B | 0% |
| 1 Nov 2023 | $184M | $129M – $388M | $274M (+49%) | after a round | 51 | growing | B | 0% |
| 1 Dec 2023 | $190M | $129M – $388M | $274M (+44%) | after a round | 51 | growing | B | 0% |
| 1 Jan 2024 | $196M | $129M – $388M | $274M (+39%) | after a round | 51 | growing | B | 0% |
| 1 Feb 2024 | $203M | $129M – $388M | $274M (+35%) | after a round | 51 | growing | B | 0% |
| 24 Feb 2024 | $851M | $739M – $1.3B | $1.1B (+30%) | after a round | 51 | growing | A | 0% |
| 1 Mar 2024 | $854M | $739M – $1.3B | $1.1B (+29%) | after a round | 78 | growing | A | 0% |
| 1 Apr 2024 | $874M | $739M – $1.3B | $1.1B (+26%) | after a round | 78 | growing | A | 0% |
| 1 May 2024 | $893M | $739M – $1.3B | $1.1B (+24%) | after a round | 78 | growing | A | 0% |
| 1 Jun 2024 | $913M | $739M – $1.3B | $1.1B (+21%) | after a round | 78 | growing | A | 0% |
| 1 Jul 2024 | $933M | $739M – $1.3B | $1.1B (+18%) | after a round | 78 | growing | A | 0% |
| 1 Aug 2024 | $1.0B | $739M – $1.4B | $1.3B (+25%) | after a round | 140 | growing | B | 0% |
| 1 Sep 2024 | $1.0B | $739M – $1.4B | $1.3B (+21%) | after a round | 140 | growing | B | 0% |
| 1 Oct 2024 | $1.1B | $739M – $1.4B | $1.3B (+17%) | after a round | 140 | growing | B | 0% |
| 1 Nov 2024 | $1.1B | $739M – $1.5B | $1.3B (+14%) | after a round | 170 | growing | B | 0% |
| 1 Dec 2024 | $1.2B | $739M – $1.5B | $1.3B (+10%) | after a round | 170 | growing | B | 0% |
| 1 Jan 2025 | $1.2B | $739M – $1.5B | $1.3B (+6%) | after a round | 170 | growing | B | 0% |
| 1 Feb 2025 | $1.3B | $739M – $1.5B | $1.3B (+3%) | after a round | 170 | growing | B | 0% |
| 18 Feb 2025 | $2.8B | $2.4B – $4.1B | $3.6B (+30%) | after a round | 170 | growing | A | 0% |
| 1 Mar 2025 | $2.8B | $2.4B – $4.1B | $3.6B (+29%) | after a round | 170 | growing | A | 0% |
| 1 Apr 2025 | $2.8B | $2.4B – $4.1B | $3.6B (+26%) | after a round | 292 | growing | A | 0% |
| 1 May 2025 | $2.9B | $2.4B – $4.1B | $3.6B (+23%) | after a round | 292 | growing | A | 0% |
| 1 Jun 2025 | $3.0B | $2.4B – $4.1B | $3.6B (+21%) | after a round | 292 | growing | A | 0% |
| 1 Jul 2025 | $3.0B | $2.4B – $4.1B | $3.6B (+18%) | after a round | 292 | growing | A | 0% |
| 1 Aug 2025 | $3.2B | $2.4B – $4.3B | $3.8B (+19%) | after a round | 370 | growing | A | 0% |
| 1 Sep 2025 | $3.3B | $2.4B – $4.3B | $3.8B (+16%) | after a round | 370 | growing | A | 0% |
| 1 Oct 2025 | $3.3B | $2.4B – $4.3B | $3.8B (+13%) | after a round | 370 | growing | A | 0% |
| 1 Nov 2025 | $3.6B | $2.4B – $4.6B | $4.0B (+11%) | after a round | 466 | growing | B | 0% |
| 1 Dec 2025 | $3.7B | $2.4B – $4.6B | $4.0B (+8%) | after a round | 466 | growing | B | 0% |
| 1 Jan 2026 | $3.8B | $2.4B – $4.6B | $4.0B (+5%) | after a round | 466 | growing | B | 0% |
| 1 Feb 2026 | $4.0B | $2.4B – $4.7B | $4.1B (+2%) | after a round | 527 | growing | B | 0% |
| 1 Mar 2026 | $4.1B | $2.4B – $4.7B | $4.1B (0%) | after a round | 527 | growing | B | 0% |
| 1 Apr 2026 | $5.3B | $4.6B – $7.9B | $6.9B (+30%) | after a round | 527 | growing | A | 0% |
| 2 Apr 2026 | $5.3B | $4.6B – $7.9B | $6.9B (+30%) | after a round | 527 | growing | A | 0% |
| 1 May 2026 | $5.4B | $4.6B – $7.9B | $6.9B (+27%) | after a round | 595 | growing | A | 0% |
| 1 Jun 2026 | $5.5B | $4.6B – $7.9B | $6.9B (+24%) | after a round | 595 | growing | A | 0% |
| 1 Jul 2026 | $5.7B | $4.6B – $7.9B | $6.9B (+22%) | after a round | 595 | growing | A | 0% |
| 1 Aug 2026 | $5.8B | $4.6B – $7.9B | $6.9B (+19%) | after a round | 595 | growing | A | 0% |
| 1 Sep 2026 | $5.9B | $4.6B – $7.9B | $6.9B (+16%) | after a round | 595 | growing | A | 0% |
| 1 Oct 2026 | $6.1B | $4.6B – $8.2B | $7.1B (+16%) | after a round | 677 | growing | A | 0% |
| 24 Oct 2026 | $6.2B | $4.6B – $8.2B | $7.1B (+14%) | after a round | 677 | growing | A | 0% |
Key facts about Abridge
- Founded
- 2018
- Headquarters
- Philadelphia, United States
- Employees
- about 677 +45% in a year
- Total raised
- $764M
- Funding rounds
- 6
- Last round
- Series E Apr 2026
Abridge was founded in 2018 by Florian Metze, Sandeep Konam and Shiv Rao.
Abridge funding history
Abridge has 6 funding rounds on record, from Jan 2019 to Apr 2026, $764M in total. The latest disclosed valuation is $5.30B post-money (Series E, Apr 2026).
Series E 1 Apr 2026
Led by Andreessen Horowitz; with Khosla Ventures, NVIDIA NVentures, Bessemer Venture Partners, Archerman Capital, California Health Care Foundation, Catalio Capital Management, Eli Lilly, Emerson Collective, Harper Ventures, Soma Capital, Wndrco.
Sources: techjacksolutions.com, startup-index.com, abridge.com and 3 more
$316M
$5.30B post-money
Series D 17 Feb 2025
Led by Elad Gil, Institutional Venture Partners; with Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures, Redpoint Ventures, Spark Capital, SV Angel.
Sources: manaventures.vc, abridge.com, fiercehealthcare.com and 2 more
$250M
$2.75B post-money
Series C 23 Feb 2024
Led by Lightspeed Venture Partners, Redpoint Ventures; with Institutional Venture Partners, Spark Capital, Union Square Ventures, Bessemer Venture Partners, Wittington Ventures, Kaiser Permanente Ventures, CVS Health Ventures, Mass General Brigham Artificial Intelligence and Digital Innovation Fund (AIDIF), ApSTAT Technologies, Gaingels, Mana Ventures, Nvidia.
Sources: fiercehealthcare.com, abridge.com, intuitionlabs.ai
$150M
$850M post-money
Series B 26 Oct 2023
Led by Spark Capital; with Bessemer Venture Partners, CVS Health Ventures, Kaiser Permanente Ventures, Lifepoint Health, Mayo Clinic, SCAN Group, UC Investments (University of California), American College of Cardiology.
Sources: abridge.com, technical.ly, fiercehealthcare.com and 1 more
$30M
Series A 11 Aug 2022
Led by Wittington Ventures; with Union Square Ventures, Bessemer Venture Partners, Pillar VC, UPMC Enterprises, Whistler Capital Partners.
Sources: abridge.com, businesswire.com, mobihealthnews.com and 4 more
$13M
Seed 31 Jan 2019
Investors not disclosed.
$5.0M
Abridge investors
39 investors have backed Abridge; Spark Capital, Lightspeed Venture Partners and Redpoint Ventures and 4 more led at least one round.
- Spark Capital lead, 3 rounds
- Lightspeed Venture Partners lead, 2 rounds
- Redpoint Ventures lead, 2 rounds
- Andreessen Horowitz lead
- Elad Gil lead
- Institutional Venture Partners lead
- Bessemer Venture Partners 5 rounds
- CVS Health Ventures 3 rounds
- California Health Care Foundation 2 rounds
- Kaiser Permanente Ventures 2 rounds
- Union Square Ventures 2 rounds
- American College of Cardiology
- ApSTAT Technologies
- Archerman Capital
- CapitalG
- Eli Lilly
- Emerson Collective
- Gaingels
- Institutional Venture Partners
- Khosla Ventures
- Lifepoint Health
- Mass General Brigham Artificial Intelligence and Digital Innovation Fund (AIDIF)
- Mayo Clinic
- NVentures
- Nvidia
- NVIDIA NVentures
- SCAN Group
- Soma Capital
- SV Angel
- UC Investments (University of California)
- UPMC Enterprises
- Wndrco
What Abridge does
Abridge works in tech companies, with 15 recorded offerings and customers in healthcare.
Abridge AI, Inc. is an American technology company engaged in generative AI solutions for healthcare. The company develops platforms that transform clinical conversations into structured clinical notes and integrates with electronic health record systems to support multi-specialty, multilingual, and integrated workflows. Abridge serves healthcare organizations and providers, including large health systems, and its solutions are designed to enhance clinical documentation efficiency and support operational workflows.
Description from Veridion's company data.
Products and services
- Generative AI Solutions Development
- Clinical Documentation Automation
- AI-Generated Clinical Note Generation
- Electronic Medical Record Integration Services
- Contextual Reasoning Engine Development
- Clinical Workflow Enhancement Solutions
- Multi-Specialty Workflow Support Services
- Multilingual Workflow Support Services
- Clinical Evidence Mapping and Verification
- Patient Care Improvement Solutions
- Revenue Cycle Efficiency Solutions
- Healthcare System Scalability Solutions
- AI-Driven Patient Care Solutions
- Healthcare AI Platform Deployment
- Healthcare AI Platform Integration
Markets
- Healthcare
Technology
- Contextual Reasoning Engine
- AI-Driven Clinical Note Generation
- AI-Driven Patient Care
- AI-Driven Clinical Documentation
- AI-Driven Workflow Automation
- AI-Driven Revenue Cycle Management
Business model
- Business-to-Business
- Software-as-a-Service
- Enterprise
Industry codes (NAICS)
- 513210 Software Publishers 100% match
Questions about Abridge
What is Abridge worth?
Valuation $6.2B (range $4.6B to $8.2B), as of 24 Oct 2026. The last disclosed valuation was $5.30B (Series E, Apr 2026).
Has Abridge raised money?
Abridge has 6 funding rounds on record, from Jan 2019 to Apr 2026, $764M in total. The latest disclosed valuation is $5.30B post-money (Series E, Apr 2026).
Who has invested in Abridge?
Spark Capital, Lightspeed Venture Partners, Redpoint Ventures, Wittington Ventures, Andreessen Horowitz and Elad Gil, and 33 more. Lead investors include Spark Capital, Lightspeed Venture Partners, Redpoint Ventures and Wittington Ventures.
How many people work at Abridge?
About 677, up 45% over the last year. Headcount grew from 21 in May 2021 to 677 in Sep 2026.
What does Abridge do?
Abridge works in tech companies, with 15 recorded offerings and customers in healthcare. Its main offerings are generative AI solutions development, clinical documentation automation and AI-Generated clinical note generation.
When was Abridge founded, and where is it based?
Abridge was founded in 2018 and is based in Philadelphia, United States. It has about 677 employees, up 45% over the last year.